FDA official logo
GSRS logoPFDA official logo

TRASTUZUMAB DUOCARMAZINE

UNII:XCR2BZ80N7
Formula:
Preferred Substance Name:TRASTUZUMAB DUOCARMAZINE
GSRS Full Record:
XCR2BZ80N7
i

  • 1642152-40-6
  • IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MUS MUSCULUS MONOCLONAL SYD977 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL SYD977 LIGHT CHAIN, DIMER, THIOETHER WITH N-((2-(2-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)ETHOXY)ETHOXY)CARBONYL)-L-VALYL-N5-(AMINOCARBONYL)-N-(4-(7-((((1S)-1-(CHLOROMETHYL)-2,3-DIHYDRO-3-((6-((4-HYDROXYBENZOYL)AMINO)IMIDAZO(1,2-A)PYRIDIN-2-YL)CARBONYL)-9-METHYL-1H-BENZ(E)INDOL-5-YL)OXY)CARBONYL)-12-HYDROXY-4-METHYL-3-OXO-2,10-DIOXA-4,7-DIAZADODEC-1-YL)PHENYL)-L-ORNITHINAMIDE
  • IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185CERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO THE PRO-DRUG SECO-DUOCARMYCINHYDROXYBENZAMIDE- AZAINDOLE (SECO-DUBA)GAMMA1 HEAVY CHAIN (1-449) (HUMANIZED VH (HOMO SAPIENS (IGHV3-66-*01 (81.60%) -(IGHD)-IGHJ6*01) (8.8.13) (1-120) -HOMO SAPIENS IGHG1*01, G1M17, NG1M1 (CH1 (121-218), HINGE (219-233),CH2 (234-343), CH3 D12>E (359), L14>M (361) (344-448), CHS K>DEL (449)) (121-449)), (223-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1-214) (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (86.30%) -IGKJ1*01) (6.3.9) (1'-107') -HOMO SAPIENS IGKC*01, KM3 (108'-214')) DIMER (229-229:232-232)-BISDISULFIDE, CONJUGATED ON AN AVERAGE OF 2 OR 4 CYSTEINES, TO SECO-DUBA VIA THE CLEAVABLE LINKER N-(2-(2- MALEIMIDOETHOXY)ETHOXYCARBONYL)-L-VALYL-L-CITRULLINYLP- AMINOBENZYLOXYCARBONYL-N-(2-(2-HYDROXYETHOXY)ETHYL)- N-(2-(METHYLAMINO)ETHYL)CARBAMOYL
  • SYD985
  • SYD-985
  • TRASTUZUMAB DUOCARMAZINE [INN]
  • TRASTUZUMAB DUOCARMAZINE [USAN]
  • TRASTUZUMAB DUOCARMAZINE [WHO-DD]




UNII - XCR2BZ80N7 | UNII Search Service